An Improved Theileria parva Sporozoite Seroneutralization Assay for the Identification of East Coast Fever Immune Correlates.

IF 3 Q3 IMMUNOLOGY Antibodies Pub Date : 2024-12-05 DOI:10.3390/antib13040100
Hannah Chege, Samuel Githigia, James Gathumbi, Naomi Chege, Rose Ojuok, Josiah Odaba, Stephen Mwalimu, Harriet Oboge, Lucilla Steinaa, Vishvanath Nene, Anna Lacasta
{"title":"An Improved <i>Theileria parva</i> Sporozoite Seroneutralization Assay for the Identification of East Coast Fever Immune Correlates.","authors":"Hannah Chege, Samuel Githigia, James Gathumbi, Naomi Chege, Rose Ojuok, Josiah Odaba, Stephen Mwalimu, Harriet Oboge, Lucilla Steinaa, Vishvanath Nene, Anna Lacasta","doi":"10.3390/antib13040100","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Immune correlates of protection are ideal tools to predict treatment or vaccine efficacy. However, the accuracy of the immune correlate and the capability to robustly predict the outcome of a vaccine candidate are determined by the performance of the in vitro immunoassay used. Several <i>Theileria parva</i> sporozoite seroneutralization assays have previously been used to assess antibody functional activities; however, a common limitation has been the need for fresh material, target cells and sporozoites, and operator-to-operator bias. An improved assay represents a positive step toward overcoming challenges associated with variability and it might provide a more reliable means of establishing an immune correlate with protection after sub-unit vaccine administration.</p><p><strong>Methods: </strong>Herein, we describe key improvements, among them, (1) the use of frozen parasites and target cells to avoid batch-to-batch variations and (2) the development of a new assay read-out based on the detection of infected cells through flow cytometry, instead of the use of Giemsa staining and microscopic evaluation, in order to improve the reproducibility of the results.</p><p><strong>Results: </strong>The improved seroneutralization assay is not only able to detect the individual neutralizing capacity of antibodies; it also detects the additive effect of antibody combinations.</p><p><strong>Conclusions: </strong>This effect is described for the first time in <i>Theileria parva</i> and is of great interest for new antigen discovery and/or the epitope discovery of already known antigens like p67, opening a new avenue for the identification of ECF immune correlates of protection and the in vitro down-selection of new <i>Theileria parva</i> vaccine candidates, thereby contributing to reducing the use of animals in challenge experiments.</p>","PeriodicalId":8188,"journal":{"name":"Antibodies","volume":"13 4","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11672397/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibodies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/antib13040100","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Immune correlates of protection are ideal tools to predict treatment or vaccine efficacy. However, the accuracy of the immune correlate and the capability to robustly predict the outcome of a vaccine candidate are determined by the performance of the in vitro immunoassay used. Several Theileria parva sporozoite seroneutralization assays have previously been used to assess antibody functional activities; however, a common limitation has been the need for fresh material, target cells and sporozoites, and operator-to-operator bias. An improved assay represents a positive step toward overcoming challenges associated with variability and it might provide a more reliable means of establishing an immune correlate with protection after sub-unit vaccine administration.

Methods: Herein, we describe key improvements, among them, (1) the use of frozen parasites and target cells to avoid batch-to-batch variations and (2) the development of a new assay read-out based on the detection of infected cells through flow cytometry, instead of the use of Giemsa staining and microscopic evaluation, in order to improve the reproducibility of the results.

Results: The improved seroneutralization assay is not only able to detect the individual neutralizing capacity of antibodies; it also detects the additive effect of antibody combinations.

Conclusions: This effect is described for the first time in Theileria parva and is of great interest for new antigen discovery and/or the epitope discovery of already known antigens like p67, opening a new avenue for the identification of ECF immune correlates of protection and the in vitro down-selection of new Theileria parva vaccine candidates, thereby contributing to reducing the use of animals in challenge experiments.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
一种改进的小芽孢杆菌孢子体血清中和法鉴定东海岸热免疫相关因子。
背景:免疫保护相关因子是预测治疗或疫苗疗效的理想工具。然而,免疫相关性的准确性和可靠预测候选疫苗结果的能力取决于所使用的体外免疫测定的性能。几种细小芽孢杆菌孢子体血清中和试验已被用于评估抗体功能活性;然而,一个常见的限制是对新鲜材料、靶细胞和孢子体的需求,以及操作员对操作员的偏见。改进的检测方法是克服与变异相关的挑战的积极步骤,它可能提供一种更可靠的方法,在亚单位疫苗接种后建立与保护相关的免疫关系。方法:本文描述了关键的改进,其中包括:(1)使用冷冻寄生虫和靶细胞来避免批次之间的差异;(2)开发了一种新的基于流式细胞术检测感染细胞的检测方法,而不是使用吉姆萨染色和显微镜评估,以提高结果的可重复性。结果:改进后的血清中和试验不仅能检测个体抗体的中和能力;它还能检测抗体组合的加性效应。结论:该效应首次在细小芽孢杆菌中被描述,对发现新的抗原和/或发现已知抗原如p67的表位具有重要意义,为鉴定ECF免疫保护相关因子和体外筛选新的细小芽孢杆菌候选疫苗开辟了新的途径,从而有助于减少在攻毒实验中使用动物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Antibodies
Antibodies IMMUNOLOGY-
CiteScore
7.10
自引率
6.40%
发文量
68
审稿时长
11 weeks
期刊介绍: Antibodies (ISSN 2073-4468), an international, peer-reviewed open access journal which provides an advanced forum for studies related to antibodies and antigens. It publishes reviews, research articles, communications and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. Full experimental and/or methodical details must be provided. Electronic files or software regarding the full details of the calculation and experimental procedure - if unable to be published in a normal way - can be deposited as supplementary material. This journal covers all topics related to antibodies and antigens, topics of interest include (but are not limited to): antibody-producing cells (including B cells), antibody structure and function, antibody-antigen interactions, Fc receptors, antibody manufacturing antibody engineering, antibody therapy, immunoassays, antibody diagnosis, tissue antigens, exogenous antigens, endogenous antigens, autoantigens, monoclonal antibodies, natural antibodies, humoral immune responses, immunoregulatory molecules.
期刊最新文献
A Strategy for Simultaneous Engineering of Interspecies Cross-Reactivity, Thermostability, and Expression of a Bispecific 5T4 x CD3 DART® Molecule for Treatment of Solid Tumors. Phenomenological Modeling of Antibody Response from Vaccine Strain Composition. Targeting CD44 and EpCAM with Antibody Dye Conjugates for the Photoimmunotherapy of Prostate Cancer. Challenges and Insights in Absolute Quantification of Recombinant Therapeutic Antibodies by Mass Spectrometry: An Introductory Review. How Broadly Neutralising Antibodies Are Redefining Immunity to Influenza.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1